OncLive SOSS

EGFR-mutated mNSCLC: Updates from WCLC 2025 - Episode 5

Reviewing the Combination Regimens and Assessing Risk-Benefit

October 24, 2025

EP. 1: Precision Medicine Correlates with Reduced Cancer Mortality Rates in EGFRm mNSCLC: Data from 1994-2020

EP. 2: Biomarker Testing: Utilization Gains Tempered by Ongoing Implementation Challenges

EP. 3: Evaluating the Frontline Treatment Options in EGFRm mNSCLC

EP. 4: FLAURA-2 Overall Survival Data and Identifying Patient Populations Benefitting from Upfront Combination Therapy

EP. 5: Reviewing the Combination Regimens and Assessing Risk-Benefit

EP. 6: AI and Computational Models Could Predict Responses and Individualize Future Treatment Decisions

EP. 7: The Challenge of Combination Therapy in the Frontline Setting

EP. 8: Redefining Tolerability Amid Treatment Discontinuation

EP. 9: The Impact of the COCOON regimen on Amivantamab Toxicities

EP. 10: Testing New Dosing Strategies to Improve Treatment Tolerability

EP. 11: Treatment Resistance Patterns Can Inform Therapy Sequencing and the Need to Rebiopsy

EP. 12: Evaluating the Benefit of Continuing the EGFR Targeted TKI in 2L Treatment

EP. 13: The Role of Tumor Agnostic Therapies in the Treatment of EGFRm mNSCLC

EP. 14: The Need to Identify Better Predictive Biomarkers for Treatment Response

EP. 15: Looking Ahead to Future Treatment Options for EGFRm mNSCLC

EP. 16: HARMONi and Ivonescimab Data from WCLC

EP. 17: Wrap Up From WCLC 2025